CIBC Raises PT on Eldorado Gold Corporation (EGO) from $23 to $32; National Bank and BofA Maintain ‘Outperform' Rating
A golden nugget illuminated under direct lighting, hinting at the value of precious metals.
While there's a mixed overall analyst sentiment on Eldorado Gold Corporation (NYSE:EGO), optimistic earnings expectations are driving confidence.
On July 15, 2025, CIBC increased its price target on Eldorado Gold Corporation (NYSE:EGO) from $23 to $32, maintaining an 'Outperform' rating. The next day, National Bank also maintained its 'Outperform' rating; however, the analyst lowered their price target from $29.57 to $27.75. Previously, BofA also decreased its price target to $20.81 on July 7, maintaining an 'Outperform' rating, citing revised Q2 commodity pricing models.
On the positive side, Zacks expressed optimism regarding the company's future, amid a consistent upward trend in earnings estimates. Analysts have projected an earnings per share (EPS) of $1.73 per share for FY25, matching last year's EPS. Accordingly, it has given a 'Buy' rating on Eldorado Gold Corporation (NYSE:EGO).
Operating in Turkey, Canada, and Greece, Eldorado Gold Corporation (NYSE:EGO) produces gold, lead, and zinc. It is included in our list of the best gold stocks.
While we acknowledge the potential of EGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 11 Most Undervalued Cloud Stocks Under $10 According to Hedge Funds and 11 Best Mineral Stocks to Buy According to Hedge Funds.
Disclosure: None.
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
B&G Foods Inc (BGS) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
Net Sales: $424.4 million, down 4.5% year-over-year. Adjusted EBITDA: $58 million, down 9.3% from the previous year. Adjusted EBITDA Margin: 13.7% of net sales. Adjusted Diluted Earnings Per Share: $0.04. Base Business Net Sales: Decreased by 4.2% year-over-year. Gross Profit: $87 million, representing 20.5% of net sales. Adjusted Gross Profit: $89.1 million, or 21% of net sales. Net Cash from Operations: $17.8 million in Q2 2025. Net Debt: Reduced to $1.957 billion at the end of Q2 2025. Interest Expense: $35.8 million for Q2 2025. Divestitures: Completed divestitures of Don Pepino, Sclafani, and Le Sueur brands. Revised Fiscal Year 2025 Guidance: Net sales of $1.83 billion to $1.88 billion; adjusted EBITDA of $273 million to $283 million; adjusted EPS of $0.50 to $0.60. Warning! GuruFocus has detected 7 Warning Signs with BGS. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points B&G Foods Inc (NYSE:BGS) demonstrated sequential improvement in trend and performance in Q2 2025 after a challenging Q1. The company completed two key divestitures, which are expected to sharpen focus, simplify the business, and improve margins and cash flow. The U.S. frozen vegetables business is expected to turn profitable in the second half of 2025, with a projected increase in segment adjusted EBITDA. B&G Foods Inc (NYSE:BGS) is committed to reducing leverage and expects to reduce it to 6x within the next 12 months. Cash flow continues to be strong, with $17.8 million generated in net cash from operations during Q2 2025, up from $11.3 million in Q2 2024. Negative Points Q2 2025 net sales were down 4.5% compared to the previous year, with base business net sales down 4.2%. Adjusted EBITDA for Q2 2025 was $58 million, a decrease of 9.3% compared to the previous year. The frozen and vegetables business unit experienced a significant decline in segment adjusted EBITDA due to higher costs and trade spend. The specialty business unit saw an 8% decline in net sales, primarily due to lower Crisco oil pricing. Selling, general, and administrative expenses increased by 9.4% in Q2 2025 compared to the previous year, impacting overall profitability. Q & A Highlights Q: Bruce, can you clarify the expected decline in core business sales for the second half of 2025? A: Yes, excluding divestitures, we expect base business sales to be down about 1% for the second half. This includes a benefit from the 53rd week, which will add approximately $15 million to $20 million in sales during the fourth quarter. Q: How are you planning to mitigate the impact of tariffs, particularly in the spices and flavor solutions segment? A: We are implementing targeted pricing actions to recover tariff costs, primarily affecting garlic and black pepper sourced from China and Vietnam. There will be some lag due to retailer lead times, but we expect to offset some of the impact with productivity and cost savings efforts. Q: Can you provide more details on the impact of recent divestitures on your guidance for the year? A: The guidance adjustment is primarily due to the divestitures. The outlook for the second half remains consistent with our expectations following the first quarter results. Q: What is the status of your spices and seasonings business, and are you seeing any benefits from increased home cooking? A: The spices and seasonings business is not fully meeting our expectations. We anticipate slight growth in the second half, supported by targeted pricing to recover tariff impacts. The category is benefiting from increased demand for fresh proteins. Q: Are there any plans to change sourcing strategies to mitigate tariff impacts on spices and seasonings? A: We are exploring alternative sourcing options, but most spices are grown in regions already subject to tariffs. We have found some alternative sources for garlic and onion outside of China, but pricing adjustments will still be necessary. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Waters Corp (WAT) Q2 2025 Earnings Call Highlights: Strong Sales Growth and Raised Guidance
Sales Growth: 9% as reported, 8% in constant currency. Non-GAAP EPS: $2.95, up 12% year-on-year. GAAP EPS: $2.47. Pharma Growth: 11% growth in the Pharma segment. Industrial Growth: 6% growth in the Industrial segment. Academic and Government: Declined 3%. Gross Margin: 58.3% for the quarter. Adjusted Operating Margin: 29.1%. Free Cash Flow: $159 million after $23 million in capital expenditures. Net Debt Position: $1.1 billion at the end of the quarter. Full Year 2025 Sales Growth Guidance: Raised to 5.5% to 7.5% in constant currency. Full Year 2025 Non-GAAP EPS Guidance: Raised to $12.95 to $13.05. Third Quarter 2025 Sales Growth Guidance: 5% to 7% in constant currency. Third Quarter 2025 EPS Guidance: $3.15 to $3.25. Warning! GuruFocus has detected 2 Warning Sign with WAT. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Waters Corp (NYSE:WAT) reported strong sales growth of 9% as reported and 8% in constant currency, exceeding the high end of their guidance. Non-GAAP earnings per share increased by 12% year-on-year to $2.95, surpassing the midpoint of their guidance. The company experienced significant growth in its LC and mass spec portfolio, with instruments growing mid-single digits and recurring revenue up 11%. Waters Corp (NYSE:WAT) raised its full-year 2025 constant currency sales growth guidance to 5.5% to 7.5% and increased its non-GAAP EPS guidance to $12.95 to $13.05. The company is successfully expanding into high-growth areas, with GLP testing revenue growing 70% year-over-year and PFAS testing revenue increasing over 50% year-over-year. Negative Points The TA division experienced weakness, particularly in macro-sensitive polymer and materials testing applications, leading to a decline in sales. Academic and government segments underperformed, declining by 3%, despite better-than-expected performance. The operating tax rate presented a $0.05 headwind to adjusted EPS due to jurisdictional mix and discrete items specific to the quarter. The company faced margin dilution from tariff surcharges, impacting the gross margin for the quarter. The TA business in the Americas declined by 20% due to macroeconomic conditions and tariff challenges affecting material science and polymers customers. Q & A Highlights Q: Can you provide an update on the replacement cycle in LC and competitive dynamics, particularly regarding the Alliance iS? A: Udit Batra, President and CEO, explained that LCMS continued to grow high single digits, with strong replacement activity across large pharma customers, especially in the US and Europe. The Alliance iS grew 300% year-over-year, contributing significantly to this growth. Additionally, the TQ Absolute XR instrument has shown exceptional robustness, allowing for significant improvements in testing capabilities. Q: Regarding the BD acquisition, what is the timeline for bringing new products to market, particularly in mass spec and MALDI for microbiology? A: Udit Batra noted that while the microbiology opportunities are not included in the deal model, the team is excited about the potential. The development of new products in this area could take two to five years, with a total addressable market of around $400 million to $500 million. Q: What are your expectations for LCMS growth in the second half of the year, given the high single-digit growth in Q2? A: Udit Batra stated that the replacement cycle remains strong, particularly in large pharma, CDMOs, and generics. The TQ Absolute XR has exceeded expectations, and the company is confident in continued growth. Amol Chaubal, CFO, added that the guidance assumes a conservative 5% instrument growth, not fully reflecting the strong funnel and momentum. Q: Can you elaborate on the margin dynamics and the impact of tariffs in Q2? A: Amol Chaubal explained that the margin impact was primarily on the gross margin line due to geographical mix and costs associated with tariff remediation. The tax rate also created a $0.05 headwind on EPS. Margins are expected to improve progressively in Q3 and Q4. Q: How sustainable is the growth in China, and what are the expectations for the second half of the year? A: Udit Batra highlighted that China grew double digits in Q2, with strength across all end markets. The company remains conservative in its guidance for the second half, assuming low to mid-single-digit growth, despite strong performance in CDMOs and battery testing. Q: What are the expectations for the academic and government (ANG) segment, given recent funding dynamics? A: Udit Batra noted that ANG declined 3% in Q2, ahead of expectations. The company remains conservative for the second half, assuming continued decline, despite some positive funding news. Growth in China was strong due to localization and modest stimulus impact. Q: How do you plan to achieve the $290 million synergy target post-acquisition of BD's Biosciences and Diagnostic Solutions? A: Udit Batra outlined that immediate impacts are expected from instrument replacement, service attach rate improvements, and e-commerce expansion. The company plans to leverage its existing operational discipline to achieve these synergies quickly. Q: What is the outlook for the drug discovery business within the pharma segment? A: Udit Batra stated that pharma drug discovery remains slow, with no significant replacement cycle activity. However, large pharma and CDMOs are experiencing healthy replacement cycles and order conversion. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
22 minutes ago
Asian shares track rally on Wall Street that won back most of Friday's wipeout
BANGKOK -- Asian shares advanced on Tuesday, following U.S. stocks higher after they won back most of their sharp loss from last week. Investors appeared to have recovered some confidence after worries over how President Donald Trump's tariffs may be punishing the economy sent a shudder through Wall Street last week. At the same time, a stunningly weak U.S. jobs report Friday raised expectations that the Federal Reserve will cut interest rates at its next meeting in September, potentially a plus for markets. This week's highlights will likely include earnings reports from The Walt Disney Co., McDonald's and Caterpillar, along with updates on U.S. business activity. In Asian trading, Tokyo's Nikkei 225 index gained 0.6% to 40,515.81, while the Kospi in South Korea jumped 1.4% to 3,192.57. In Hong Kong, the Hang Seng rose 0.3% to 24,799.67. The Shanghai Composite index was up 0.5% at 3,602.13. Australia's S&P/ASX 200 jumped 1.1% to 8,759.90, while the SET in Thailand also gained 1.1%. India's Sensex was the sole outlier, losing 0.5% on concerns over trade tensions with the United States, with the Trump administration insisting on cutbacks in oil purchases from Russia. India has indicated that it will continue buying oil from Russia, saying its relationship with Moscow was 'steady and time-tested,' and that its stance on securing its energy needs is guided by the availability of oil in the markets and prevailing global circumstances. 'Trump's threats of 'substantial' tariff hikes on account of imports of Russian crude pose a quagmire for India,' Mizuho Bank said in a commentary. 'Between exacerbated U.S.-imposed geo-economic headwinds and financial/macro setbacks from Russian oil advantages lost, pain will be hard to avert.' On Monday, the S&P 500 jumped 1.5% to 6,329.94. The Dow Jones Industrial Average climbed 1.3%, or 585.06 points, to 44,173.64. The Nasdaq composite leaped 2% to 21,053.58. Idexx Laboratories helped Wall Street recover from its worst day since May, soaring 27.5% after the seller of veterinary instruments and other health care products reported a stronger profit for the spring than analysts expected. The pressure is on U.S. companies to deliver bigger profits after their stock prices shot to record after record recently. Reports from big U.S. companies have largely come in better than expected and could help steady a U.S. stock market that may have been due for some turbulence. A jump in stock prices from a low point in April had raised criticism that the broad market had become too expensive. Tyson Foods likewise delivered a bigger-than-expected profit for the latest quarter, and the company behind the Jimmy Dean and Hillshire Farms brands rose 2.4%. They helped make up for a nearly 3% loss for Berkshire Hathaway after Warren Buffett's company reported a drop in profit for its latest quarter from a year earlier. The drop-off was due in part to the falling value of its investment in Kraft Heinz. American Eagle Outfitters jumped 23.6% after Trump weighed in on the debate surrounding the retailer's advertisements, which highlight actor Sydney Sweeney's great jeans. Some critics thought the reference to the blonde-haired and blue-eyed actor's 'great genes' may be extolling a narrow set of beauty standards. 'Go get 'em Sydney!' Trump said on his social media network. Wayfair climbed 12.7% after the retailer of furniture and home decor said accelerating growth helped it make more in profit and revenue during the spring than analysts expected. Tesla rose 2.2% after awarding CEO Elon Musk 96 million shares of restricted stock valued at approximately $29 billion. The move could alleviate worries that Musk may leave the company. In other dealings early Tuesday, U.S. benchmark crude oil shed 9 cents to $66.20 per barrel while Brent crude, the international standard, gave up 8 cents to $68.68 per barrel. The U.S. dollar was unchanged at 147.09 Japanese yen. The euro slipped to $1.1555 from $1.1573.
